Navigation Links
Gen-Probe Borrows $170 Million Under New Line of Credit
Date:3/2/2009

SAN DIEGO, Calif., March 2 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that it is borrowing $170 million under a newly issued line of credit to finance its pending acquisition of Tepnel Life Sciences PLC and other general corporate activities, including its existing share repurchase program.

The Company will pay interest on the one-year, $180 million revolving credit facility, provided by Bank of America, at a floating rate 0.6 percent above the one-month London Interbank Offered Rate (LIBOR), which was approximately 0.5 percent earlier today.

"In today's difficult economic environment, Gen-Probe's strong balance sheet and cash flow enable us to access external liquidity more cost-effectively than if we were to sell assets from our own short-term investment portfolio, which totaled $505 million at year-end and currently yields 2.9% on an after-tax basis," said Herm Rosenman, the Company's senior vice president, finance, and chief financial officer.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release relating to expectations, beliefs, plans, objectives, assumptions
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
2. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
5. Carl Hull Named President and Chief Operating Officer of Gen-Probe
6. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
7. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
8. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
9. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
10. Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference
11. Lucy Shapiro, Ph.D., Elected to Gen-Probe Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 Kitware, a leader ... tool that enables the exploration of hospital costs ... in response to the recent release of “Medicare Provider ... top 100 most-billed procedures from the Centers for Medicare ... for similar procedures at hospitals across the country has ...
(Date:5/17/2013)... May 17, 2013 Topricin Pain ... Inc., has been listed among nationally recommended over-the-counter ... initiative conducted by "U.S. News" Health in collaboration ... the “No. 1 Pharmacists Recommended designation” in ... national OTC brands, and is the only homeopathic ...
(Date:5/17/2013)... world-leading provider of scientific, technical and medical information products ... study in Reproductive BioMedicine Online ... an abnormal chromosomal composition can be identified by the ... classifying the risk of genetic abnormality without a biopsy. ... a retrospective study, using their predictive model to assess ...
(Date:5/17/2013)... , May 17, 2013  Yongye International, Inc. (NASDAQ: ... leading developer, manufacturer, and distributor of crop nutrient products ... , today announced that, on May 16, 2013, the ... directors (the "Board of Directors") was provided a letter ... Hong Kong ) Limited ("Abax") to Full Alliance ...
Breaking Biology Technology:Kitware Enables Interactive Exploration of CMS Medicare Data 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Breakthrough for IVF? 2Breakthrough for IVF? 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... 5 , - Data Presented ... York , ThromboGenics NV (Euronext Brussels: ... innovative medicines for eye,disease, vascular disease and cancer, today announces ... the treatment of,Diabetic Macular Edema (MIVI II DME). The data ...
... , LA JOLLA, Calif., Oct. 5 Transdel Pharmaceuticals, Inc. ... a conference call and audio webcast on Tuesday, October 6, ... of its Phase 3 clinical study for Ketotransdel®, a topical ... A press release will be issued on Tuesday, October 6, ...
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... bavituximab in combination with carboplatin and paclitaxel in patients ... reported from the initial cohort of 21 patients in ... patients with locally advanced or metastatic NSCLC achieved an ...
Cached Biology Technology:ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 2ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 4Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) 2Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 4
(Date:5/19/2013)... have engineered a strain of electricity-producing bacteria that can ... and carbon dioxide as its sole source of carbon. ... their findings at the 113th General Meeting of the ... result of current production solely on hydrogen," says Amit ... his co-authors are part of the Lovley Lab Group ...
(Date:5/18/2013)... presented today at Digestive Disease Week (DDW) explores new ... impact of coffee on autoimmune disease and palliative care ... has been associated with reduced risk of fibrosis, a ... of java each month also correlate with lower risk ... Mayo Clinic, Rochester, MN, linked coffee consumption with reduced ...
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... a mile below the ocean surface donot bother ... to one spot. Fornourishment, they rely completely onsymbiotic ... sulphurous volcanicsoup in which they both thrive. , ... bacteria-free, with a completedigestive system. Juveniles swim, hunt, ...
... in some animals to periodically wake up while hibernating may ... researchers at Penn State. The finding could offer an insight ... and has potential implications for human health. , ... part of a unique strategy to get past harsh winters ...
... It may be possible to protect the testes of cancer ... scientist told the 22nd annual conference of the European Society ... Tuesday 20 June 2006. Mr. Alon Carmely from ... for the first time that the injection of a drug ...
Cached Biology News:Giant deep-sea tubeworm's meal ticket comes in as a skin infection 2Giant deep-sea tubeworm's meal ticket comes in as a skin infection 3Breaks in hibernation help fight bugs 2Injection may prevent infertility in men receiving cancer chemotherapy 2
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
... all types of yeast two-hybrid studies, including complex interaction ... Choice of two bait vectors for maximum flexibility ... Triple reporter strain NMY51 ensures ... Complete set of controls: pLexA-p53, pLexA-lamin C ...
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Biology Products: